The purpose of this survey is to evaluate the long-term safety and effectiveness of vedolizumab for intravenous (IV) infusion 300 milligrams (mg) in Crohn's disease (CD) patients in the routine clinical setting.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants who have One or More Adverse Events
Timeframe: Up to Week 54
Number of Participants who have One or More Adverse Drug Reactions
Timeframe: Up to Week 54